Earnings Feed
Start Free
HALOZYME THERAPEUTICS, INC.·4

Feb 24, 6:14 PM ET

LaBrosse Nicole 4

4 · HALOZYME THERAPEUTICS, INC. · Filed Feb 24, 2026

Insider Transaction Report

Form 4
Period: 2026-02-20
HALOZYME THERAPEUTICS, INC.HALO
LaBrosse Nicole
SVP, CHIEF FINANCIAL OFFICER
Transactions
  • Exercise/Conversion

    Common Stock

    2026-02-20+5,332→ 38,290 total
  • Tax Payment

    Common Stock

    [F1]
    2026-02-20$70.98/sh−2,876$204,138→ 35,414 total
  • Exercise/Conversion

    Common Stock

    2026-02-23+6,688→ 42,102 total
  • Tax Payment

    Common Stock

    [F2]
    2026-02-23$70.64/sh−3,608$254,869→ 38,494 total
  • Exercise/Conversion

    Restricted Stock Units

    [F3]
    2026-02-20−5,332→ 15,995 total
    Exercise: $0.00→ Common Stock (5,332 underlying)
  • Exercise/Conversion

    Performance Stock Units

    [F3]
    2026-02-23−6,688→ 36,357 total
    Exercise: $0.00→ Common Stock (6,688 underlying)
Footnotes (3)
  • [F1]The reported disposition of 2,876 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
  • [F2]The reported disposition of 3,608 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
  • [F3]This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.
Signature
/s/ James R. Oehler, Attorney-in-Fact|2026-02-24

Documents

1 file
  • 4
    wk-form4_1771974883.xmlPrimary

    FORM 4